Biomarkers for prostate cancer detection

Expert Review of Anticancer Therapy

Volumn 10, Issue 1, 2010, Pages 103-114

  Reed, Amanda Beth ^a   Parekh, Dipen J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Biomarkers; Cancer; Prostate; Prostate specific antigen; PSA; Tumor markers

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; AUTOANTIBODY; EARLY PROSTATE CANCER ANTIGEN; EARLY PROSTATE CANCER ANTIGEN 2; GLUTATHIONE TRANSFERASE; GOLGI MEMBRANE PROTEIN 1; HEPSIN; KALLIKREIN; KALLIKREIN 2; MEMBRANE PROTEIN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; GENE EXPRESSION REGULATION; GENE FUSION; GENE TRANSLOCATION; HUMAN; LONGITUDINAL STUDY; METHYLATION; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEOMICS; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

ANIMALS; HUMANS; MALE; MASS SCREENING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 74749109815     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.168     Document Type: Review

References (114)

1. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324(17), 1156-1161 (1991).
2. Loeb S, Gonzalez CM, Roehl KA et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J. Urol. 175(3 Pt 1), 902-906 (2006).
3. Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch. Ital. Urol. Androl. 78(4), 125-129 (2006).
4. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93(14), 1054-1061 (2001).
5. Nilsson BO, Carlsson L, Larsson A, Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Ups. J. Med. Sci. 106(1), 43-49 (2001).
6. Bradley SV, Oravecz-Wilson KI, Bougeard G et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res. 65(10), 4126-4133 (2005).
7. Semmes OJ, Malik G, Ward M. Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. J. Cell. Biochem. 98(3), 496-503 (2006).
8. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3(4), 267-275 (2003).
9. Adam BL, Qu Y, Davis JW et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62(13), 3609-3614 (2002).
10. Petricoin EF 3rd, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 94(20), 1576-1578 (2002).
11. Banks RE, Stanley AJ, Cairns DA et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 51(9), 1637-1649 (2005).
12. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96(5), 353-356 (2004).
13. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl Cancer Inst. 97(4), 307-309 (2005).
14. Grizzle WE, Semmes OJ, Basler J et al. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: a study in biomarker validation in genitourinary oncology. Urol. Oncol. 22(4), 337-343 (2004).
15. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58(3), 411-416 (2001).
16. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67(2), 316-320 (2006).
17. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N. Engl. J. Med. 350(22), 2239-2246 (2004). •• Discusses findings revealing that biopsy-detected prostate cancer, including high-grade cancer, is not rare among men with prostate-specific antigen (PSA) levels of 4.0 ng/ml or less - levels generally thought to be in the 'normal' range.
18. Lilja H, Ulmert D, Bjork T et al. Longterm prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J. Clin. Oncol. 25(4), 431-436 (2007).
19. Vickers AJ, Ulmert D, Serio AM et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int. J. Cancer 121(10), 2212-2217 (2007).
20. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J. Urol. 172(1), 90-93 (2004).
21. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostatespecific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294(1), 66-70 (2005).
22. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16), 2215-2220 (1992).
23. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 147(3 Pt 2), 817-821 (1992).
24. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J. Urol. 153(4), 1160-1163 (1995).
25. Schmid HP. Tumour markers in patients on deferred treatment: prostate specific antigen doubling times. Cancer Surv. 23, 157-167 (1995).
26. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J. Natl Cancer Inst. 98(8), 529-534 (2006).
27. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274(15), 1214-1220 (1995).
28. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279(19), 1542-1547 (1998).
29. Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56(2), 255-260 (2000).
30. Mikolajczyk SD, Rittenhouse HG. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease. Rinsho Byori 52(3), 223-230 (2004).
31. Catalona WJ, Bartsch G, Rittenhouse HG et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J. Urol. 170(6 Pt 1), 2181-2185 (2003).
32. Catalona WJ, Bartsch G, Rittenhouse HG et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J. Urol. 171(6 Pt 1), 2239-2244 (2004).
33. Khan MA, Sokoll LJ, Chan DW et al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 64(6), 1160-1164 (2004).
34. Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF, Stampfer MJ. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiol. Biomarkers Prev. 13(10), 1640-1645 (2004).
35. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360(13), 1310-1319 (2009). •• After 7-10 years of follow-up in two groups, PSA-screened men versus a usual-care control group, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.
36. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1328 (2009). •• PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of over diagnosis. This study showed that 1410 men would need to be screened and 48 additional cases of prostate cancer would need to be treated to prevent one death from prostate cancer.
37. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin. Chem. 54(12), 1951-1960 (2008).
38. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9(11), 1133-1147 (2000).
39. Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J. Urol. 13(3), 238-243 (2006).
40. Kurek R, Nunez G, Tselis N et al. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin. Cancer Res. 10(17), 5808-5814 (2004).
41. Dhir R, Vietmeier B, Arlotti J et al. Early identification of individuals with prostate cancer in negative biopsies. J. Urol. 171(4), 1419-1423 (2004).
42. Paul B, Dhir R, Landsittel D, Hitchens MR, Getzenberg RH. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res. 65(10), 4097-4100 (2005).
43. Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J. Urol. 174(2), 514-518 (2005).
44. Leman ES, Cannon GW, Trock BJ et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69(4), 714-720 (2007).
45. Narod SA, Seth A, Nam R. Fusion in the ETS gene family and prostate cancer. Br. J. Cancer 99(6), 847-851 (2008).
46. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748), 644-648 (2005).
47. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45(7), 717-719 (2006).
48. Yoshimoto M, Joshua AM, Chilton-Macneill S et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8(6), 465-469 (2006).
49. Rajput AB, Miller MA, De Luca A et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 60(11), 1238-1243 (2007).
50. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31), 4596-4599 (2007).
51. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66(17), 8337-8341 (2006).
52. Mehra R, Tomlins SA, Shen R et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 20(5), 538-544 (2007).
53. Mosquera JM, Perner S, Demichelis F et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J. Pathol. 212(1), 91-101 (2007).
54. Nam RK, Sugar L, Wang Z et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 6(1), 40-45 (2007).
55. Petrovics G, Liu A, Shaheduzzaman S et al. Frequent overexpression of ETSrelated gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24(23), 3847-3852 (2005).
56. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol. Rep. 17(5), 1033-1036 (2007).
57. Lapointe J, Kim YH, Miller MA et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Pathol. 20(4), 467-473 (2007).
58. Laxman B, Tomlins SA, Mehra R et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8(10), 885-888 (2006).
59. Rubin MA, Zhou M, Dhanasekaran SM et al. a-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287(13), 1662-1670 (2002).
60. Luo J, Zha S, Gage WR et al. a-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62(8), 2220-2226 (2002).
61. Sreekumar A, Laxman B, Rhodes DR et al. Humoral immune response to a-methylacyl-CoA racemase and prostate cancer. J. Natl Cancer Inst. 96(11), 834-843 (2004).
62. Zielie PJ, Mobley JA, Ebb RG, Jiang Z, Blute RD, Ho SM. A novel diagnostic test for prostate cancer emerges from the determination of a-methylacyl-coenzyme a racemase in prostatic secretions. J. Urol. 172(3), 1130-1133 (2004).
63. Reiter RE, Gu Z, Watabe T et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95(4), 1735-1740 (1998).
64. Gu Z, Thomas G, Yamashiro J et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19(10), 1288-1296 (2000).
65. Han KR, Seligson DB, Liu X et al. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J. Urol. 171(3), 1117-1121 (2004).
66. Ross S, Spencer SD, Holcomb I et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 62(9), 2546-2553 (2002).
67. Raff AB, Gray A, Kast WM. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 277(2), 126-132 (2009).
68. Visakorpi T, Kallioniemi AH, Syvanen AC et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55(2), 342-347 (1995).
69. Sato K, Qian J, Slezak JM et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl Cancer Inst. 91(18), 1574-1580 (1999).
70. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57(3), 524-531 (1997).
71. Qian J, Bostwick DG, Takahashi S et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. 55(22), 5408-5414 (1995).
72. Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer research. Curr. Opin. Urol. 12(5), 401-406 (2002).
73. Hara N, Kasahara T, Kawasaki T et al. Reverse transcription- polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin. Cancer Res. 8(6), 1794-1799 (2002).
74. Jeronimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93(22), 1747-1752 (2001).
75. Lee WH, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91(24), 11733-11737 (1994).
76. Lin X, Tascilar M, Lee WH et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159(5), 1815-1826 (2001).
77. Jeronimo C, Varzim G, Henrique R et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 11(5), 445-450 (2002).
78. Brooks JD, Weinstein M, Lin X et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev. 7(6), 531-536 (1998).
79. Harden SV, Sanderson H, Goodman SN et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J. Natl Cancer Inst. 95(21), 1634-1637 (2003).
80. Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J. Urol. 169(3), 1138-1142 (2003).
81. Goessl C, Muller M, Heicappell R et al. Methylation-specific PCR for detection of neoplastic DNA in biopsy washings. J. Pathol. 196(3), 331-334 (2002).
82. Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 63(2), 414-418 (2004).
83. Crocitto LE, Korns D, Kretzner L et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 64(4), 821-825 (2004).
84. Goessl C, Muller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58(3), 335-338 (2001).
85. Hoque MO, Topaloglu O, Begum S et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. 23(27), 6569-6575 (2005).
86. Cairns P, Esteller M, Herman JG et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7(9), 2727-2730 (2001).
87. Goessl C, Krause H, Muller M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60(21), 5941-5945 (2000).
88. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 9(7), 2673-2677 (2003).
89. Roupret M, Hupertan V, Yates DR et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res. 13(6), 1720-1725 (2007).
90. Magee JA, Araki T, Patil S et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61(15), 5692-5696 (2001).
91. Stephan C, Yousef GM, Scorilas A et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J. Urol. 171(1), 187-191 (2004).
92. de Kok JB, Verhaegh GW, Roelofs RW et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62(9), 2695-2698 (2002).
93. Fradet Y, Saad F, Aprikian A et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64(2), 311-315 (2004).
94. Marks LS, Fradet Y, Deras IL et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69(3), 532-535 (2007).
95. van Gils MP, Hessels D, van Hooij O et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 13(3), 939-943 (2007).
96. Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52(6), 1089-1095 (2006).
97. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol. 179(5), 1804-1809 (2008).
98. Varambally S, Laxman B, Mehra R et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 10(11), 1285-1294 (2008).
99. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001).
100. Lapointe J, Li C, Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101(3), 811-816 (2004).
101. Laxman B, Morris DS, Yu J et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68(3), 645-649 (2008).
102. Steuber T, Helo P, Lilja H. Circulating biomarkers for prostate cancer. World J. Urol. 25(2), 111-119 (2007).
103. Bossuyt PM, Reitsma JB, Bruns DE et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem. 49(1), 7-18 (2003).
104. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). Nat. Clin. Pract. Urol. 2(8), 416-422 (2005).
105. Srivastava S, Kramer BS. Early detection cancer research network. Lab. Invest. 80(8), 1147-1148 (2000).
106. Dobbin KK, Simon RM. Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics 8(1), 101-117 (2007).
107. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 39(1), 207-215 (1983).
108. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N. Engl. J. Med. 349(4), 335-342 (2003).
109. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349(3), 215-224 (2003).
110. Thompson IM, Chi C, Ankerst DP et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J. Natl Cancer Inst. 98(16), 1128-1133 (2006).
111. Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71(2 Suppl.), 589-593 (1993).
112. Parekh DJ, Ankerst DP, Baillargeon J et al. Assessment of 54 biomarkers for biopsydetectable prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16(10), 1966-1972 (2007).
113. Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353(12), 1224-1235 (2005).
114. Website 201 Prostate-Specific Antigen Best Practice Statement: 2009 Update www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ mainreports/psa09.pdf •• Provides current information on the use of PSA testing for the evaluation of men at risk, risks and benefits of early detection, assistance in pretreatment staging or risk assessment, post-treatment monitoring, and use as a guide in management of men who recur after primary or secondary therapy.